An FDA Act that may be relvant to ATL-1102 FDA, page-211

I listened again to the webinar posted on the PPMD site In the Pipeline: Reducing Inflammation, featuring 4 speakers including our CMO. The standard of care is corticosteroids. One quickly gains the impression from the line of questioning that if there were viable alternatives for the treatment of inflammation, corticosteroids would be dropped in a heartbeat. Okay, we know that already.

What we don't know is what is happening behind the scenes to bring ATL1102 to America. There is a sense of urgency particularly with the approval of a number of dystrophin producing drugs. One participant in the session stated that it was critically important to protect the dystrophin. This is one of the outstanding hopes that ATL1102 will work synergistically with exon skipping and gene therapy drugs.